81 related articles for article (PubMed ID: 10763417)
1. [Current chemotherapy of locally advanced or metastatic bladder tumors].
Dourthe LM; Ceccaldi B; Fournier R; Houlgatte A; Merrer J
Ann Urol (Paris); 2000 Feb; 34(1):3-8. PubMed ID: 10763417
[TBL] [Abstract][Full Text] [Related]
2. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
3. Update on chemotherapy for advanced bladder cancer.
Rosenberg JE; Carroll PR; Small EJ
J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
5. Systemic chemotherapy options for metastatic bladder cancer.
Siefker-Radtke A
Expert Rev Anticancer Ther; 2006 Jun; 6(6):877-85. PubMed ID: 16761931
[TBL] [Abstract][Full Text] [Related]
6. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
7. [Simultaneous chemotherapy/radiotherapy in locally advanced unresectable cancer of the bladder].
Paule B; Saint F
Prog Urol; 2001 Feb; 11(1):132-40. PubMed ID: 11296634
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy.
Lehmann J; Retz M; Stöckle M
World J Urol; 2002 Aug; 20(3):144-50. PubMed ID: 12196897
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy agents in transitional cell carcinoma: the old and the new.
Maluf FC; Bajorin DF
Semin Urol Oncol; 2001 Feb; 19(1):2-8. PubMed ID: 11246730
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy in metastatic and locally advanced non-small cell lung cancer.
Spigel DR; Greco FA
Semin Surg Oncol; 2003; 21(2):98-110. PubMed ID: 14508860
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review.
Pectasides D; Pectasides M; Nikolaou M
Eur Urol; 2005 Jul; 48(1):60-7; discussion 67-8. PubMed ID: 15967253
[TBL] [Abstract][Full Text] [Related]
14. [Bladder cancer chemotherapy practice study].
Clippe C; Clippe S; Yzebe D; Flechon A; Droz JP
Prog Urol; 2002 Sep; 12(4):609-14. PubMed ID: 12463119
[TBL] [Abstract][Full Text] [Related]
15. Progress in the chemotherapy of metastatic cancer of the urinary tract.
Raghavan D
Cancer; 2003 Apr; 97(8 Suppl):2050-5. PubMed ID: 12673696
[TBL] [Abstract][Full Text] [Related]
16. Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Azuma H; Yamamoto K; Inamoto T; Ibuki N; Kotake Y; Sakamoto T; Kiyama S; Ubai T; Takahara K; Segawa N; Narumi Y; Katsuoka Y
Am J Clin Oncol; 2009 Dec; 32(6):592-606. PubMed ID: 19593084
[TBL] [Abstract][Full Text] [Related]
17. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
Mulatero C; McClaren BR; Mason M; Oliver RT; Gallagher CJ
Br J Cancer; 2000 Dec; 83(12):1612-6. PubMed ID: 11104554
[TBL] [Abstract][Full Text] [Related]
18. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
Pollera CF; Nelli F
Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
[TBL] [Abstract][Full Text] [Related]
19. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
